摘要
目前新生血管性年龄相关性黄斑变性(neovascular age-related macular degeneration,nAMD)首选治疗方法为抗血管内皮生长因子(vascular endothelial growth factor,VEGF).基于雷珠单抗临床研究数据,抗VEGF在临床上的应用方案,不断得到优化.目前雷珠单抗治疗方案主要有:每月治疗方案、每两月治疗方案、每季度治疗方案、按需治疗(Pro Re Nata,PRN)方案、治疗并延长方案、观察与计划方案等.最初的每月治疗方案可以使患者获得显著的视力提高;然而每月治疗会给患者带来巨大的经济负担.PRN方案、每两个月治疗方案、每季度治疗方案等都可以减少患者的玻璃体注射次数,从而减少患者的经济负担,而治疗与延长方案不但减少了患者的注射次数,同时也减少了随访次数,减少经济成本的同时也节约了时间负担.
The currently accepted treatment for neovascular age-related macular degeneration (nAMD) is anti-vascular endothelial growth factor (VEGF).Based on the clinical data of ranibizumab,the clinical application of anti-VEGF is continuously optimized.At present,the treatment of ranibizumab mainly includes:monthly treatment plan,bi-month treatment plan,quarterly treatment plan,on-demand treatment (Pro Re Nata,PRN) program,treatment and extension program,observation and plan plan.The initial monthly treatment plan can give patients a significant increase in vision;however,monthly treatment can place a huge financial burden on patients.The PRN program,every two months of treatment,and quarterly treatments can reduce the number of vitreous injections in patients,thereby reducing the financial burden on patients,while treatment and extension programs not only reduce the number of injections,but also reduce the number of follow-ups.It also saves time and burden while reducing economic costs.
作者
石佳
孙大卫
Shi Jia;Sun Dawei(Department of Ophthalmology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)
出处
《国际眼科纵览》
2019年第2期111-117,共7页
International Review of Ophthalmology
基金
国家自然科学基金项目(81171381).
作者简介
通信作者:孙大卫,Email:drsundw@126.com.
